Roflumilast Investigator Chief Medical Officer Forest Research Institute Inc. / Regulatory Affairs Forest Research Institute Inc. / /
Event
FDA Phase / /
Facility
Medicine University of Connecticut Health Center Farmington / Chapel Hill Gillings School / Respiratory Medicine University / Pulmonary Medicine University of North Carolina / Biostatistics The University of North Carolina / Internal Medicine University / /
Pulmonary-Allergy Drugs Advisory Committee / FDA Oncologic Drugs Advisory Committee / London School of Medicine and Dentistry Barts / University of North Carolina / London NHS Trust London / FDA / University of North Carolina / Chapel Hill / Pulmonary Medicine University / Chapel Hill Gillings School of Global Public Health Chapel Hill / Respiratory Medicine University of Liverpool Honorary Consultant Physician University Hospital Aintree Liverpool / Oxford University / Regulatory Affairs Forest Research Institute / Advisory Committee / Medicine University of Connecticut Health Center Farmington / Biostatistics Department / Investigator Chief Medical Officer Forest Research Institute / /
Person
Klaus F. Rabe / Lisa Travis / Perspective James Donohue / Neil Barnes / Stephen Rennard / Phillip Schein / Marco Taglietti / /
Position
Professor / Department / Professor of Respiratory Medicine London Chest Hospital Barts / Professor / Professor of Medicine / Department of Pulmonology Leiden University Medical Center / Director / Professor of Internal Medicine University of Nebraska Medical Center / Chair / Chief / /
Daxas® (roflumilast) Tablets NDA[removed]Pulmonary-Allergy Drugs Advisory Committee Meeting April 7, 2010